Biondo Investment Advisors Lifted Vertex Pharmaceuticals (VRTX) Holding By $3.96 Million; 2 Bullish Analysts Covering Amphion Innovations Plc (LON:AMP)

February 17, 2018 - By Louis Casey

Biondo Investment Advisors Llc increased Vertex Pharmaceuticals Inc (VRTX) stake by 869.17% reported in 2017Q3 SEC filing. Biondo Investment Advisors Llc acquired 26,075 shares as Vertex Pharmaceuticals Inc (VRTX)’s stock rose 33.61%. The Biondo Investment Advisors Llc holds 29,075 shares with $4.42 million value, up from 3,000 last quarter. Vertex Pharmaceuticals Inc now has $40.70B valuation. The stock decreased 0.14% or $0.22 during the last trading session, reaching $160.72. About 1.00M shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 17, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Among 2 analysts covering Amphion Innovations PLC (LON:AMP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amphion Innovations PLC had 16 analyst reports since September 4, 2015 according to SRatingsIntel. The rating was maintained by Beaufort Securities on Friday, June 24 with “Speculative Buy”. The company was maintained on Thursday, April 28 by Northland Capital. On Friday, September 11 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The stock of Amphion Innovations Plc (LON:AMP) has “Speculative Buy” rating given on Friday, November 6 by Beaufort Securities. The rating was maintained by Beaufort Securities on Friday, April 8 with “Speculative Buy”. The firm earned “Corporate” rating on Thursday, November 23 by Northland Capital. The firm has “Corporate” rating by Northland Capital given on Wednesday, June 28. The stock has “Corporate” rating by Northland Capital on Wednesday, May 31. The rating was maintained by Beaufort Securities with “Speculative Buy” on Friday, September 4. On Friday, September 29 the stock rating was maintained by Northland Capital with “Corporate”. See Amphion Innovations Plc (LON:AMP) latest ratings:

22/12/2017 Broker: Northland Capital Rating: Corporate Maintain
23/11/2017 Broker: Northland Capital Rating: Corporate Maintain
10/11/2017 Broker: Northland Capital Rating: Corporate Maintain
05/10/2017 Broker: Northland Capital Rating: Corporate Maintain
29/09/2017 Broker: Northland Capital Rating: Corporate Maintain

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold VRTX shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Jacobs Levy Equity Inc stated it has 0.55% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ls Advsr Ltd Liability Corporation stated it has 6,900 shares or 0.06% of all its holdings. Cornerstone Advisors owns 14,000 shares. Ghost Tree Capital Limited Company holds 1.61% or 50,000 shares in its portfolio. Capital One Natl Association holds 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2,662 shares. 2.70M were reported by Goldman Sachs Group. Cibc Asset Mgmt reported 31,852 shares. Westpac Banking reported 76,052 shares stake. Princeton Capital Mgmt holds 1.74% or 22,609 shares. Btim holds 2,183 shares or 0.01% of its portfolio. 88,535 are held by Nuveen Asset Lc. Smithfield Tru holds 0.02% or 890 shares. Kingdon Mgmt Lc invested in 35,612 shares or 0.35% of the stock. Research Mngmt Com has 0.44% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Advisor Prtn Ltd Liability Corp reported 0.15% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 96 analyst reports since July 31, 2015 according to SRatingsIntel. Raymond James upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, July 19 to “Outperform” rating. Argus Research upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, September 28 to “Buy” rating. BMO Capital Markets maintained it with “Buy” rating and $184.0 target in Tuesday, January 2 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Robert W. Baird on Wednesday, January 31. Needham upgraded the stock to “Buy” rating in Friday, June 23 report. The rating was maintained by Leerink Swann on Tuesday, March 8 with “Outperform”. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Tuesday, August 1 by Cowen & Co. The rating was maintained by Maxim Group on Wednesday, July 19 with “Buy”. As per Thursday, September 29, the company rating was maintained by Jefferies. On Thursday, July 27 the stock rating was maintained by Maxim Group with “Buy”.

Since August 31, 2017, it had 0 buys, and 37 selling transactions for $109.10 million activity. Another trade for 3,450 shares valued at $600,680 was made by Parini Michael on Thursday, February 1. Another trade for 5,435 shares valued at $891,487 was made by Silva Paul M on Monday, January 22. ALTSHULER DAVID had sold 56,250 shares worth $8.83 million on Tuesday, January 16. 10,753 shares valued at $1.68M were sold by Bhatia Sangeeta N. on Friday, January 5. $334,232 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by SMITH IAN F on Tuesday, January 16. $675,750 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Arbuckle Stuart A. On Tuesday, January 16 LEIDEN JEFFREY M sold $15.63M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 99,563 shares.

Biondo Investment Advisors Llc decreased Jpmorgan Chase & Co stake by 97,810 shares to 172,472 valued at $9.32 million in 2017Q3. It also reduced Bank Amer Corp stake by 353,425 shares and now owns 873,455 shares. Core Laboratories N V (NYSE:CLB) was reduced too.

It closed at GBX 1.375 lastly. It is down 0.00% since February 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment decreased to 0.97 in 2017 Q3. Its down 0.15, from 1.12 in 2017Q2. It worsened, as 35 investors sold Amphion Innovations Plc shares while 228 reduced holdings. 76 funds opened positions while 178 raised stakes. 116.09 million shares or 1.34% more from 114.55 million shares in 2017Q2 were reported. 136,613 were reported by Wellington Management Limited Liability Partnership. Capstone reported 3,000 shares. First Business Finance Services owns 4,513 shares for 0.13% of their portfolio. Meag Munich Ergo Kapitalanlagegesellschaft Mbh holds 61,011 shares. Regentatlantic has 0.07% invested in Amphion Innovations Plc (LON:AMP). Susquehanna Grp Llp stated it has 0% of its portfolio in Amphion Innovations Plc (LON:AMP). Walleye Trading Limited Liability Corporation holds 0.01% or 7,015 shares in its portfolio. Aureus Asset Limited invested 0.04% of its portfolio in Amphion Innovations Plc (LON:AMP). Strs Ohio has invested 0% in Amphion Innovations Plc (LON:AMP). Benjamin F Edwards invested 0% of its portfolio in Amphion Innovations Plc (LON:AMP). Palisade Asset Management Ltd Limited Liability Company reported 0.1% stake. 27,523 were accumulated by Caisse De Depot Et Placement Du Quebec. Aviance Cap Partners Ltd reported 0.36% in Amphion Innovations Plc (LON:AMP). Conning Incorporated has invested 0.05% in Amphion Innovations Plc (LON:AMP). Axa holds 0.25% or 393,747 shares in its portfolio.

Amphion Innovations plc is a venture capital firm specializing in both public and private early stage investments and spun out of universities and firms. The company has market cap of 2.89 million GBP. It does not invest in “speculative” technologies requiring long development timeframes or excessive capital investment. It currently has negative earnings. It invests in the medical, life sciences, and technology sectors with defensible core intellectual property, know-how and growth potential in very large markets of at least $1 billion in size together with firms, governments, universities, and entrepreneurs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Louis Casey

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: